Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ICML 2023 | Future work in mantle cell lymphoma

Preetesh Jain • 15 Jun 2023
ICML 2023
Lymphoma Mantle Cell Lymphoma Non-Hodgkin Lymphoma

Preetesh Jain, MD, PhD, The University of Texas MD Anderson Cancer Center, Houston, TX, provides an insight into upcoming studies in mantle cell lymphoma (MCL), highlighting that new molecules must be designed for patients, to reflect the unique nature of the disease. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultant or advisory role: Kite, Eli Lilly, Loxo oncology
Honoraria: Aptitude health, pharmacy times
Research funding: Astra Zeneca, Kite, beigene
Educational grants: Dava oncology

More from Preetesh Jain

5:06
Trials of interest in the mantle cell lymphoma space at ASH 2023
Preetesh Jain • 8 Dec 2023
1:32
Selecting BTK inhibitors for patients with MCL
Preetesh Jain • 15 Jun 2023
1:18
The unmet needs of patients with MCL who relapse after CAR-T
Preetesh Jain • 15 Jun 2023
1:56
The impact of the tumor microenvironment on patient outcomes and BTKi resistance in MCL
Preetesh Jain • 15 Jun 2023

Related Videos

2:04
Salvage treatment options following CAR-T failure in DLBCL
Jaromir Tomasik • 17 Apr 2024
1:55
Exploring first-line CAR-T therapy for the treatment of DLBCL
Wendy Osborne • 22 Apr 2024
3:29
CAR-T therapy as the SoC in 2L LBCL and barriers that remain
Wendy Osborne • 22 Apr 2024
2:11
The role of CAR-T therapy for lymphoma in 2024: expert session highlights
Sridhar Chaganti • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals